Publication date: Aug 15, 2025
In addition to neutralization, Fc effector function contributes to vaccine-mediated protection against severe SARS-CoV-2 infection. However, differential coordination and cross-reactivity of Fc effector functions across vaccines is not clearly defined. A secondary analysis of three vaccines with BNT162b2, Ad26. CoV2. S (NCT04838795), and ChAdOx1 nCoV-19 (NCT04444674) reveals that BNT162b2 elicits the highest levels of binding, neutralization, and Fc effector function with antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), and complement deposition (ADCD) significantly differing by vaccine modality. Ad26. CoV2. S showed low ADCD activity before a homologous boost, which significantly increased this function. BNT162b2 vaccination triggered higher levels of cross-reactive neutralization, ADCC and ADCP than the adenoviral vaccines, while ChAdOx1 nCoV-19 exhibited higher ADCD cross-reactivity. Coordination between functions all varied by modality, with vaccination eliciting neutralization and binding correlations with ADCC for BNT162b2, but with ADCD following Ad26. CoV2. S vaccination. This supports the optimization of Fc effector functions for improved polyfunctional vaccine design.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Cov2 | Clinical microbiology |
| Low | Immune response |
| Nct04838795 | Virology |
| Phagocytosis | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | IDO | immune response |